India’s pharma rise driven by innovation push: Ex-US NIH Director

InternationalIANS
Advertisement
Boston, May 1 : India’s emergence as a global pharmaceutical powerhouse is entering a new phase, driven by innovation, vaccine leadership and expanding clinical capabilities, according to Dr Elias Zerhouni, former Director of the US National Institutes of Health (NIH).

Zerhouni said the India-US relationship in healthcare and biotechnology has steadily strengthened over the years, moving beyond manufacturing to innovation-led collaboration.

“There’s a tremendous amount of exchanges and a presence of now larger and larger Indian companies, Lupin and Sun Pharma, and many others,” he told IANS in an interview. “I’ve seen an ascending and increasing relationship, which now is getting even better because I think we’re not just using or working with India as a manufacturing country, but also as an innovative country.”

The top American scientist said India continues to dominate in generics and active pharmaceutical ingredients (APIs), forming a critical backbone of global drug supply. “India is very strong in chemistry and all the APIs… they come either from India or from China,” he noted, adding that the country remains “a major source of generic principle drugs.”

But Zerhouni said India’s role has expanded beyond generics. He pointed to the country’s vaccine manufacturing capacity as a defining global contribution. “Without Indian contributions to the manufacturing of vaccines like the India Serum Institute, it would be very hard to immunise the population around the world,” he said.

He highlighted India’s approach to “frugal innovation” as a key differentiator. “Innovation that doesn’t cost such an amount of money that people don’t have access to it… I think that’s in the culture in India,” he said.

On pandemic lessons, Zerhouni said the COVID-19 crisis exposed vulnerabilities in global supply chains and forced countries to rethink health security. “We discovered that we were not set up very well for a pandemic situation or a global health emergency,” he said.

India and the US, as two large democracies, rely more on private-sector collaboration than central planning to address such challenges. “I don’t know that there is a grand plan… I think it’s the goodwill and the economic incentives that will drive that,” he said.

Reflecting on his experience with NIH collaborations in India, he noted bureaucratic delays as a key hurdle. He recalled engaging with then Prime Minister Manmohan Singh to address delays in grant approvals. “We are democratic, right, but also bureaucratic, both the US and India,” he said.

On clinical trials, he said India is still at an early stage but improving. “Clinical trials are very sensitive… the sites have to be capable,” he said, adding that regulatory systems and research culture are evolving.

Responding to a question, he pointed to a broader geopolitical shift benefiting India. “There’s a pivot right now… a lot of people are pivoting outside of China… to India in many ways,” he said, citing rising collaboration in medical technology and biomedical research.

Zerhouni identified contrasting healthcare challenges in the US and India. “In healthcare, America is the cost… people cannot afford the very expensive medications,” he said, while India’s focus remains on expanding access.

Artificial intelligence is also reshaping the sector, though its impact remains incremental. “It has improved the speed, improved the quality… but it has not really discovered anything that we didn’t know,” he said.

He described biotechnology as entering a “multipolar” phase, with India, China, and other nations contributing to innovation. “I don’t care where the cure comes from. I want patients to be cured,” he said.

Zerhouni, a physician-scientist, served as a faculty member at Johns Hopkins University School of Medicine and was executive vice-dean from 1996 to 2002. He later served as the 15th Director of the US National Institutes of Health from May 2, 2002, to October 31, 2008, under the George W. Bush administration, and was appointed as one of the first US presidential science envoys in 2009.

He was also a senior fellow at the Bill and Melinda Gates Foundation from 2009 to 2010.

Advertisement

Note: The content of this article is sourced from a news agency and has not been edited by the ap7am team.

Elias ZerhouniIndia pharmaUS NIHIndia-US healthcarevaccine manufacturinggeneric drugsfrugal innovationclinical trials IndiaManmohan Singhbiomedical research

More News

Telangana: All-India Police Band competition begins in Hyderabad

16 Nov, 19:00

FM Sitharaman chairs 2nd pre-Budget consultation with leading agriculture, rural development experts

16 Nov, 18:58

Democracy under threat in Andhra Pradesh: YSRCP

16 Nov, 18:55

Indian diaspora in Manila hails PM Modi’s Philippines visit

16 Nov, 18:52

Another Italian Senator condemns Filibeck's remarks on Indian democracy

16 Nov, 18:49

‘Hoping he has 3-4 more years,’ says Faf du Plessis on Virat Kohli’s IPL playing future

16 Nov, 17:09

Telangana BJP lodges complaint with FRRO against foreign delegates at Bharat Summit

16 Nov, 17:07

Kulgam attack: Two LeT terrorists, including Latief Bhat, killed in encounter

16 Nov, 17:06

Members of Indian community extend warm welcome to PM Modi in Manila

16 Nov, 17:05

BCCI congratulates Jay Shah on being reelected as ICC

16 Nov, 17:04

Sensex jumps over 500 points as bank, FMCG stocks shine

16 Nov, 16:03

Patidar’s unbeaten 135 powers MP to 131-run win; Uttarakhand, J&K and UP also register victories

16 Nov, 15:49

PM Modi arrives in Manila to attend ASEAN-India Summit and East Asia Summit

16 Nov, 15:32

Salman Khan shot in freezing water for 6 hours, ate food in wet clothes, says ‘Maatrubhumi’ director

16 Nov, 15:30

Encounter breaks out between security forces and terrorists in J&K’s Kulgam

16 Nov, 15:29

SC suspends sentence, grants bail to two convicts in Bilkis Bano gang-rape case

16 Nov, 15:14

Sachin plays gully cricket with UK's Prince William and Princess Kate

16 Nov, 15:13

BLA sharpens military strategy, appoints ex-Pakistan Army Captain as chief

16 Nov, 14:49

Sachin backs Jay Shah’s vision for cricket’s growth, wishes him success for second term as ICC Chair

16 Nov, 14:18

Trump ‘very positive’ on long-term friendship between India and US: IBM CEO

16 Nov, 14:09
..More News